Omalizumab therapy is associated with reduced circulating basophil populations in asthmatic children

D. A. Hill, M. C. Siracusa, K. R. Ruymann, E. D. Tait Wojno, David Artis, Jonathan M. Spergel

Research output: Contribution to journalArticlepeer-review

37 Scopus citations


Basophils have been implicated in promoting the early development of T H2 cell responses in some murine models of TH2 cytokine-associated inflammation. However, the specific role of basophils in allergic asthma remains an active area of research. Recent studies in animal models and human subjects suggest that IgE may regulate the homeostasis of human basophil populations. Here, we examine basophil populations in children with severe asthma before and during therapy with the IgE-directed monoclonal antibody omalizumab. Omalizumab therapy was associated with a significant reduction in circulating basophil numbers, a finding that was concurrent with improved clinical outcomes. The observation that circulating basophils are reduced following omalizumab therapy supports a mechanistic link between IgE levels and circulating basophil populations, and may provide new insights into one mechanism by which omalizumab improves asthma symptoms.

Original languageEnglish (US)
Pages (from-to)674-677
Number of pages4
JournalAllergy: European Journal of Allergy and Clinical Immunology
Issue number5
StatePublished - 2014
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology


  • IgE
  • allergy
  • asthma
  • basophil
  • omalizumab


Dive into the research topics of 'Omalizumab therapy is associated with reduced circulating basophil populations in asthmatic children'. Together they form a unique fingerprint.

Cite this